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ABSTRACT
Formation of metastases, also known as cancer dissemination, is an important stage of breast cancer (BrCa)
development. KISS1 expression is associated with inhibition of metastases development. Recently we have
demonstrated that BrCa metastases to the brain exhibit low levels of KISS1 expression at both mRNA and
protein levels. By using multicolor immunofluorescence and coculture techniques here we show that
normal adult astrocytes in the brain are capable of promoting metastatic transformation of circulating
breast cancer cells localized to the brain through secretion of chemokine CXCL12. The latter was found in
this study to downregulate KISS1 expression at the post-transcriptional level via induction of microRNA-
345 (MIR345). Furthermore, we demonstrated that ectopic expression of KISS1 downregulates ATG5 and
ATG7, 2 key modulators of autophagy, and works concurrently with autophagy inhibitors, thereby
implicating autophagy in the mechanism of KISS1-mediated BrCa metastatic transformation. We also
found that expression of KISS1 in human breast tumor specimens inversely correlates with that of MMP9
and IL8, implicated in the mechanism of metastatic invasion, thereby supporting the role of KISS1 as a
potential regulator of BrCa metastatic invasion in the brain. This conclusion is further supported by the
ability of KISS1, ectopically overexpressed from an adenoviral vector in MDA-MB-231Br cells with silenced
expression of the endogenous gene, to revert invasive phenotype of those cells. Taken together, our
results strongly suggest that human adult astrocytes can promote brain invasion of the brain-localized
circulating breast cancer cells by upregulating autophagy signaling pathways via the CXCL12-MIR345-
KISS1 axis.
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Introduction
Breast cancer (BrCa) is the most common primary malignancy
of women, accounting for almost 30% of all female cancers
worldwide. Breast cancer mortality is associated with the dis-
semination of cancer cells to multiple organs such as lungs,
bones and brain.1 The mechanism of BrCa dissemination is
complex and involves several genes,2 some of which serve as
mediators, while others as suppressors3 of metastasis. Among
the suppressors, the KISS1/kisspeptin 1 (KiSS-1 metastasis-sup-
pressor) gene deserves special attention. This gene encodes a
145-amino acid (aa) precursor peptide that becomes cleaved
into several short peptides of 104-, 13- and 14 aa in length.
KISS1 inhibits growth and invasion of osteosarcoma5 and pros-
tate cancer cells.6
Whereas deficiency of KISS1 expression in tumor tissues is
associated with cancer progression,7 overexpression of this
protein can suppresses the formation of metastases8 via
molecular mechanisms involving KISS1R9 and CXCR410
receptors. Although, our group11 and others12 have found a
significant reduction in KISS1 expression in BrCa metastases
to the brain relative to primary BrCa tumors, the precise role
of KISS1 in the development and progression of brain metas-
tases remains unknown. The objective of this study was to
investigate the role of KISS1 in modulating brain metastases
and to reveal the upstream and the downstream effectors of
KISS1 downregulation.
Development of brain metastases is a result of complex
interplay between the tumor cells and the tumor environ-
ment,13 which is represented predominantly by normal astro-
cytes in the brain tissue. Astrocytes regulate the brain response
to inflammation,14 maintain brain homeostasis15 and provide
protection of neurons from hypoxia.16 Conversely, reactive
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astrocytes can play a mitogenic role by secreting interleukins
and chemokines, such as CCL2 and CXCL12/SDF1, respec-
tively. The latter can serve as a chemoattractant for highly met-
astatic CXCR4C cells.17 Elevated levels of CCL2 and CXCL12
expression have also been linked to tumor progression and
development of metastases.18 Although normal astrocytes have
been linked with tumor progression,14 the role of these cells in
brain metastases is still unclear. Here we provide the first evi-
dence that normal astrocytes can promote brain metastases
through downregulation of KISS1 and activation of the auto-
phagy survival pathway in circulating BrCa cells.
Results
Primary tumors release KISS1-expressing cancer stem cells
into the bloodstream
BrCa is represented by highly heterogeneous tumor types,19
each containing a distinctive population of cancer cells with
stem cell properties,20 resistance to conventional BrCa thera-
pies,21 and capability of migrating22 and initiating metastases
in the brain. We hypothesized that blood-circulating cancer
stem cells (CSC) with a self-renewal property and a KISS1-defi-
cient phenotype could give rise to metastatic foci in the brain.
To identify and isolate a population of circulating tumor cells
(CTCs), we used a previously described23 MDA-MB-231 meta-
static model of human BrCa in mice.24 We observed a strong
association between primary tumor growth and number of
CTCs in the blood (Fig. S1A to D). Using an in vitro tumorige-
nicity analysis we showed that CD24¡/LOW and CD44C cells
exhibit a »7.2- and »1.48-fold higher potential to form tumors
as compared with CD24C and CD44C or parental cells, respec-
tively (Fig. S1E, P < 0.05), which highlights their potential for
forming secondary tumors. In addition, flow cytometry
together with the ALDEFLUOR assay25 (Fig. S1F) demonstrate
that the CD24¡/LOW and CD44C population of CSCs isolated
from blood (CTC) is metabolically active. We also observed
that the CD24¡ and CD44C population of CTCs isolated from
nude mice with established MDA-MB-231 mammary tumor
xenografts exhibits a 4.7-fold higher expression of KISS1
mRNA (Fig. S1G), compared with parental CSCs (P < 0.05).
There was, however, no correlation between the KISS1 mRNA
levels and those of the ST6GALNAC6 gene,26 implicated in
priming BrCa cells to the brain (Fig. S1H).
Cancer stem cells, identified in BrCa brain metastases by
CD44, CD24 and FLOT2 markers, express low level of KISS1
Our next step was to characterize expression of KISS1 in a
small subset of metastatic cells called cancer stem cells (CSCs),
identified by expression of stem cell markers CD44 and CD2427
in the primary brain metastatic tissue. Given the low expression
levels of KISS1 in BrCa brain metastases,11 we hypothesized
that high expression of KISS1 in CTCs entering the brain could
be locally modulated by the brain tissue environment. As evi-
dent from Fig. 1A, RONC1 and RONC-BM35 tumor speci-
mens are composed of either distinct CD24- or CD44-positive
cells, since no overlap in cell populations expressing those sur-
face markers was observed. Therefore, we characterized CD44C
CSC populations expressing FLOT2/ESA128 and KISS1. At the
onset, we identified a CD44C, FLOT2C and KISS1¡ CSC popu-
lation that exhibited colocalization of only 2 distinct IF signals
(red and green, respectively), resulting in sky blue cell staining,
and subsequently looked for subpopulations also positive for
KISS1 expression (CD44C, FLOT2C and KISS1C) by triple IF
staining. These experiments revealed cells with “white” colocal-
ization signal (Fig. 1B,C). While the stem cell population in the
primary tumors comprised KISS1-positive (KISS1C) subtypes
(average 0.95 § 0.44 per high power field, Fig. 1D), brain meta-
static lesions contained mostly KISS1-negative stem cells (aver-
age 1.8 § 0.85 per high power field, Fig. 1D) These data are
consistent with our earlier finding that brain metastatic lesions
exhibit drastically lower KISS1 expression levels relative to pri-
mary BrCa tumors.11
Normal human astrocytes downregulate KISS1 in brain
metastases via production of CCL2 and CXCL12
At the next step we determined the region in brain that can
modulate KISS1 expression. Given the fact that astrocytes are
capable of modulating biologic properties and behavior of can-
cer cells,12 we hypothesized that they could induce formation
of brain metastases through suppression of KISS1 expression
among BrCa cells, entering into the brain. For instance, a triple
IF staining of brain metastatic specimens for an astrocyte-spe-
cific marker GFAP, a stem cell marker, and CD44 and KISS1
showed that CD44C and KISS1C BrCa cells tend to lose KISS1
expression (red in Fig. 2A) after coming into direct contact
with GFAP-positive astrocytes (green in Fig. 2A). To find out if
human adult astrocytes are capable of modulating KISS1
expression in BrCa CTCs, we examined the level of KISS1
expression in GFP-tagged cancer cells (CN34-GFP, CN34Br-
GFP, MDA-MB-231Br-GFP and 4T1Br-GFP) by coculturing
them with normal human astrocytes (NHA) or human micro-
glia (HM) in vitro (Fig. 2B, C). Although we observed that only
parental CN34 BrCa cells upon their coculturing with astro-
cytes or human microglia induce KISS1 mRNA (P < 0.05), the
brain-primed metastatic MDA-MB-231Br, CN34Br or 4T1Br
cancer cells exhibited greater level of KISS1 downregulation
(»65%, »82% and »52% reduction vs Mock, respectively) as a
result of direct contact with astrocytes. This effect was mediated
by a 10- to 1000-fold increase in CXCL1 (P D 0.02), CCL2 (P D
0.015) and CXCL12 (P D 0.023) mRNA expression levels in
astrocytes (Fig. 2D) induced through contact with the cancer
cells. Furthermore, we discovered that KISS1 expression in
CN34Br cells gets selectively inhibited by human CXCL12 and
CCL2 proteins in a dose-dependent manner (Fig. 2E, P <
0.05), which was further confirmed by IF staining (data not
shown). While no colocalization was observed for CCL2 and
astrocyte-specific GFAP staining (Fig. 2F, left panels), a distinc-
tive colocalization (yellow and orange signal on merged
images) was observed for CXCL12 and GFAP markers in brain
metastatic tissues (Fig. 2F, right panels), highlighting the clini-
cal significance of CXCL12C and GFAPC reactive astrocytes for
the survival of patients with BrCa brain metastases after surgery
(Fig. 2G). As expected, the presence of CXCL12¡ and GFAPC
cells in BrCa brain metastatic tissue associates with longer
patient survival (38.75 § 23.6 vs 104 § 20.6 days, P D 0.019)
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KISS1 mRNA is a direct target for MIR345
It remains unclear how the CXCL12 chemokine, released by
astrocytes, modulates KISS1 expression. Since treatment of
BrCa cells with CXCL12 has been shown to induce expression
of cellular microRNAs,29 and suppression of CXCL12 has been
found to reduce cancer cell metastases,30 we hypothesized that
CXCL12 could induce a KISS1-targeting microRNA, silencing
expression of KISS1 mRNA in metastatic BrCa cells (Fig. S2).
In line with the above possibility, some experimental data (Ula-
sov et al., unpublished) indicated to MIR345 and MIR146B as
best candidates for the role of post-transcriptional regulators of
KISS1 expression, since their induction inversely correlated
with KISS1 expression levels in primary tumors, based on
quantitative PCR analyses of cancer patient samples. Con-
versely, among 5 candidate miRNAs with predicted ability to
bind (base pair to) the 30 UTR of the human KISS1 mRNA
(TargetScan-based computational analysis), MIR345 and
MIR146B were the only ones whose expression in CN34Br and
MDA-MB-231Br brain metastatic cells increased in response to
treatment with CXCL12 or CCL2 proteins (Fig. 3A). Indeed,
CXCL12 was experimentally confirmed to induce the expres-
sion of MIR345 in a dose-dependent manner, whereas Gene
Ontology analysis indicated that MIR345 could potentially
modulate a cytokine-mediated signaling pathway (Fig. 3B, P D
0.0007, FDR<2%). Thus regulation of KISS1 expression at
post-transcriptional level in response to CXCL12 or CCL2 was
assumed and further directly validated by in vitro assays, using
cancer cells stably expressing GFP or Luciferase (Luc) reporters,
fused to the 30UTR sequence (bearing potential MIR345 target
site) of the human KISS1 mRNA. Expression of the reporters
was analyzed following treatment of the transfected cells with
NHA-conditioned media or individual recombinant CCL2 or
CXCL12 proteins (Fig. S3). Alternatively, the reporter gene
expression was analyzed following a direct transfection of the
cells with human MIR345–5p mimic. As expected, treatment
with either purified CXCL12 (P D 0.003) or MIR345–5p mimic
(P D 0.018) significantly decreased expression of GFP from the
Figure 1. Detection of CSC in the primary BrCa specimens and brain metastatic lesions by immunofluorescence. (A) Double staining of primary BrCa and BrCa metastatic
tumors in the brain specimens for stem cell markers CD44 (green membrane staining) and CD24 (red membrane staining) reveals 2 distinct populations of cancer cells
(red and green) with no detectable signal colocalization (yellow). (B, C) A 4-color immunostaining reveals loss of KISS1 expression in the BrCa stem cell population of brain
metastases. (B) A representative (merged) image (400X, scale bar: 20 mm) showing colocalization of KISS1 with CD44 (magenta signals), but not with CD24 in primary
BrCa specimen (RONC1), suggesting that KISS1 is expressed in primary BrCa cells or CSC; KISS1 pseudo-colored with red; CD24 with green; CD44 with blue; and DAPI with
gray. (C) Representative (merged) images (400X, scale bar: 20 mm) of brain metastatic tumor (RONC-BM and RONC-BM35) specimens, showing colocalization of CD44
with FLOT2 (sky blue signal indicated by arrow), but not KISS1, in contrast to primary (RONC1) tumors, where CD44 and FLOT2 colocalize with KISS1 resulting in numerous
white foci (dashed arrow), not present in metastases; CD44 (blue membrane staining), KISS1 (red cytoplasmic and nuclear staining), DAPI (gray nuclear staining), FLOT2
(green cytoplasmic and membrane staining); Insets (white boxes) show portions of the corresponding images of primary (RONC1, panel B) or metastatic (RONC-BM and
RONC-BM35, panel C) tumor specimens at higher magnification. (D) Quantitative assessment of CSC with no KISS1 expression (CD44C, FLOT2C and KISS1¡, sky blue) and
KISS1-positive (CD44C, FLOT2C andKISS1C, white foci) CSC in primary and the brain metastatic specimens (white and black bars, respectively). The amount of KISS1-posi-
tive and negative CSC was determined in unmatched specimens (primary BrCa, N D 4) and BrCa metastases to the brain (ND 4) by counting sky-blue and white foci of IF
signals on merged images. Each tumor type was analyzed in triplicates with 5 high power fields (HPF) § SD (standard deviation) and minimum 50 cells per slide.
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GFP-KISS1–30UTR (Fig. 3C,D,F,G and S3) reporter construct
(at 1 ng/ml) in CN34Br cells. A similar inhibitory effect was
observed upon treatment of CN34Br cells with astrocyte-condi-
tioned media (P D 0.038), which could be reversed by addition
of AMD3100 (P D 0.007 relative to NHA-conditioned media
treatment), a chemical inhibitor of CXCR4 signaling (Fig. 3E,
H), strongly supporting involvement of CXCR4 in the mecha-
nism of KISS1 downregulation. Conversely, transfection of
MDA-MB-231Br cells with MIR345–5p mimic inhibited
expression of KISS1 mRNA (Fig. 4A, P D 0.038) or Luc-KISS1–
30UTR (Fig. 4B) reporter fusions by 50 to 60% relative to untar-
geted (“nontargeting”) control miRNA (P D 0.016). On the
contrary, no change in Luc expression was observed for a MUT
30UTR construct bearing a mutation in the MIR345 binding
side within the KISS1 mRNA 30UTR sequence (Fig. S4). Finally,
our data suggest that the expression of MIR345 in tumors
Figure 2. Normal astrocytes downregulate KISS1 in circulating BrCa cells via production of CXCL12/SDF1. (A) Immunofluorescence staining of brain metastatic specimen for
KISS1 (red), stem cell marker CD44 (blue) and astrocyte marker GFAP (green), demonstrating that CD44C and KISS1C cancer stem cells (magenta colocalization signals) in
the central part of the tumor (indicated by dashed arrows) loose expression of KISS1 (CD44C and KISS1¡ cells indicated by white solid arrows) upon contact with astro-
cytes that occurs at the tumor edge, i.e. the area of tumor invasion into the normal brain tissue. The white dashed line represents the physical edge of the tissue speci-
men; image magnification is 400X, scale bar: 20 mm. (B) Quantitative PCR analysis of KISS1 mRNA expression in GFP-labeled CN34 or brain metastatic CN34Br BrCa cells
with or without coculturing with either human astrocytes or human microglia cells (1:1 ratio). Expression of KISS1 mRNA was determined in FACS-sorted GFP-positive cells.
Total RNA was isolated as described in Materials and Methods, converted to cDNA and KISS1 mRNA expression was quantified by RT-qPCR using the DDCt method. Results
were plotted after normalization to ACTB and presented as KISS1 mRNA expression. Experiment was performed twice in triplicate. Red bars, KISS1 mRNA in mock-treated
control cells; blue bars, KISS1 mRNA in cancer cells cocultured with human astrocytes; black bars, KISS1 mRNA expression in the presence of human microglia; P values
were determined using a Student t test; P < 0.05 indicates a significant difference in KISS1 mRNA expression relative to mock-treated control cells. (C) RT-qPCR analysis of
KISS1 mRNA expression in GFP-labeled MDA-MB-231Br or 4T1Br metastatic BrCa cells after their coculturing with normal astrocytes (human or mouse, normal astrocytes
(NA) coculture) or culturing in the presence of astrocyte conditioned medium (NA cond. medium) plotted as a bar graph. The experiment reveals downregulation of KISS1
expression upon contact with astrocytes or astrocyte-conditioned medium. Red bars, expression in mock treated cells; blue bars, expression following coculturing with
astrocytes; green bars, expression resulting from incubation in astrocyte-conditioned medium. Experiment was performed twice in triplicate; P < 0.05 relative to mock-
treated cells determined by the Student t test indicates statistical significance. (D) GFP-negative population of astrocytes cocultured with CN34Br cells were isolated by
flow cytometry and total RNA was analyzed by real-time PCR to determine expression of various chemokines. Quantitative PCR for relative expression of the most regu-
lated human chemokines CCL2, CCL3, CCL8, CXCL12 and CXCL1 was performed using cDNA from astrocytes cultured with (blue bars) or without (mock/red bars) CN34Br
metastatic BrCa cells and presented as chemokine mRNA expression per housekeeping b-actin/ACTB mRNA (normalization control). Experiment was performed twice with
5 replicates per sample; P < 0.05 indicates statistical significance of changes assessed by a Student t test. (E) Treatment of CN34Br metastatic BrCa cells with recombinant
CCL2 or CXCL12 proteins decreases KISS1 mRNA levels as revealed by RT-qPCR analysis. Expression of KISS1 mRNA in the presence of 1 (red bars), 10 (blue bars) or 50
(white bars) ng/ml of human CCL2, CXCL12, CXCL1 or CCL8 chemokines was analyzed and presented as KISS1 mRNA copy number per ACTB; P < 0.05 indicate statistically
significant differences determined by a Student t test. (F) Immunofluorescent detection of CCL2 or CXCL12 expression in GFAP-positive astrocytes. Paraffin-embedded brain
metastatic tissue specimens were stained with GFAP (green signal), CXCL12/SDF1 or CCL2 (red signal) antibodies as described in Materials and Methods. Cells were
counter-stained with DAPI for nuclei (blue). White dashed lines delineate tumor boundaries. White arrows indicate GFAPC and CXCL12C cells (yellow and orange colocaliza-
tion signals). Image magnification is 400X, scale bar: 20 mm. (G) Analysis of possible correlation between survival of patients with BrCa brain metastases and the presence
of GFAPC and CXCL12C astrocytes (with metastasis-induced CXCL12 and SDF1-expression) in their brain tissue specimens. The presence of CXCL12C- and GFAPC-positive
astrocytes in metastatic tumor specimens inversely correlates with patient survival. Data presented as survival mean § SD for each patient plotted against the number of
GFAPC and CXCL12C cells; P value was calculated (relative to GFAPC and CXCL12¡ patients) by a Student t test with Welch correction; P D 0.019.
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Figure 3. Downregulation of KISS1 by astrocyte-produced cytokines CXCL12 and CCL2 is mediated by a cellular MIR345. (A) A dose-dependent effect of CCL2 and CXCL12
cytokines on the expression of MIR345 and MIR146B in CN34Br or MDA-MB-231Br BrCa brain metastatic cells 6 h after treatment of the cells with: 1 ng/ml (red bar), 10 ng/ml
(blue bar) and 100 ng/ml (black bar) of either cytokine as determined by RT-qPCR. The data are presented as each miRNA copy number per RNU6–2 (RNA, U6 small nuclear).
Data represent results of 2 independent experiments, each performed in triplicates. (B) GO analysis of signaling pathways affected by cellular MIR345 or MIR146B. The signaling
pathway annotations were made based on scoring and evaluation of the pathways selected from the KEGG database (http://www.genome.jp/kegg). Although 22 pathways
(GO term) with various P values were found to be regulated by MIR345 or MIR146B, only statistically-enriched pathways (P < 0.05) are shown for simplification. For a
complete list of pathways and analysis details please refer to Fig. S11. ((C)and F) Downregulation of KISS1 expression by CCL2 and CXCL12 proteins (at 1 ng/ml each) via
a miRNA-mediated KISS1 mRNA silencing as revealed by immunofluorescent analysis of CN34Br metastatic BrCa cells stably expressing a GFP-KISS1¡30UTR fusion reporter.
The data summarize the results of 2 independent experiments, each performed in duplicates. Image magnification is 200X, scale bar: 50 mm (C). Quantitative analysis of
GFP expression was performed using fluorescent images acquired by using a Nikon camera and ImageJ software; signal intensity from the region of interest (ROI) was
quantified using an ROI manager. Data presented as an average ROI for each fluorescence image and sample; closed diamonds, mock-treated control cells; squares,
CCL2-treated cells; closed triangles, CXCL12-treated cells; P values for changes vs mock-treated cells were calculated using the Student t test (F). (D and G) Puromycin-
resistant CN34Br cells stably expressing a GFP-KISS1¡30UTR fusion reporter were transfected with the miRIDIAN precursor of human “mimic miRNA” MIR345–5p or a non-
targeting miRNA as a negative control using a DharmaFECT1 transfection reagent; Nontransfected control cells were used as a (mock) control. Image magnification is
200X; scale bar: 50 mm (D). Quantitative analysis of GFP reporter expression was performed using fluorescent images collected 48 h post transfection, and analyzed (8
images per sample) by ImageJ after subtracting the background; other details as in (C). Closed diamonds, mock-treated cells; closed squares, nontargeting miRNA (Nc
miRNA); closed triangles, MIR345–5p; P value of 0.018 relates to differences versus cells treated with nontargeting miRNA calculated using the Student
t test (G). ((E)and H) Treatment of puromycin-resistant CB34Br cells stably expressing a GFP-KISS1 30UTR fusion reporter with conditioned media from normal human astro-
cytes (NHA) demonstrates silencing of GFP expression in vitro. However, this silencing effect is attenuated in the presence of the CXCR4 inhibitor AMD3100. Images of
BrCa cells were acquired after 48 h of incubation in the presence of astrocyte conditioned media§ AMD3100; image magnification is 200X, scale bar is 50 mm (E); Quanti-
fication details are as in G; closed squares-mock treated CB34Br cells; closed triangles-cells treated with NHA conditioned media; closed inverted triangles-cells pretreated
with AMD3100 and incubated with NHA-conditioned media (H).
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inversely correlates with the KISS1 mRNA levels, whereas low
expression of this miRNA is associated with longer survival of
the patients with brain metastases (Fig. 4C,D). Altogether, our
findings suggest that in CSC downregulation of KISS1 expres-
sion occurs on a post-transcriptional (mRNA) level through
expression of cellular MIR345 modulated by the NHA-released
chemokine CXCL12.
KISS1 inhibition promotes autophagy
Although BrCa cells can easily migrate to the brain, their sur-
vival in the brain tissue environment becomes a serious chal-
lenge. Because BCL2 expression is known31,32 to be associated
with cell survival and promoted by autophagy as well as antia-
poptotic mechanisms, and since our data presented in Fig. 1
suggest a correlation between survival of tumor stem cells and
their KISS1 deficiency, we stained primary specimens with
BCL2- and KISS1-specific antibodies. We found a large popula-
tion of brain-localized metastatic BrCa cells with upregulated
BCL2, a marker of apoptotic resistance and autophagy survival
(Fig. 5A,B), that were deficient in KISS1 expression. This find-
ing suggests that KISS1 could be involved in the mechanism of
cancer cell survival in the brain. To find out if KISS1 expression
prevents metastatic cell survival in the brain, we ectopically
overexpressed KISS1 in metastatic BrCa cells (Fig. S5). We
observed that overexpression of KISS1 reduces ATG5 and
ATG7 and inhibits conversion of LC3-I to LC3-II (Fig. 5C,D),
which links KISS1 overexpression to autophagy inhibition. On
the contrary, downregulation of KISS1 with the KISS1-KD61
shRNA construct reduces cellular accumulation of SQSTM1/
p62 (1.47-fold). It has been shown that inhibition of SQSTM1
causes autophagic cell death in several human carcinoma
cells.33 Our data suggests that SQSTM1 downregulation is
accompanied by upregulation of ATG5 (1.5-fold), ATG7 (1.4-
fold) and conversion of LC3-I to LC3-II (autophagy markers),
(Fig. 5E to H) in brain metastatic cells. This observation sug-
gests that KISS1 expression can directly modulate autophagy.
Besides, siRNA-mediated silencing of Kiss1 improved the sur-
vival of 4T1Br BrCa cells (Fig. S6A) by suppressing apoptosis
(Fig. S6C). In addition, KISS1 overexpression increased apopto-
sis (Fig. S6D). Furthermore, KISS1 knockdown resulted in the
upregulation of BECN1/Beclin 1 mRNA (Fig. S7) and downre-
gulation of SQSTM1 (Fig. 6A,B). Consistently with our obser-
vations, ectopic expression of KISS1 reduced ATG5 and ATG7
expression, while increasing accumulation of SQSTM1
(Fig. 6A). On the other hand, 3-methyladenine (3-Ma) inhibi-
tor significantly suppressed autophagy in KISS1-KD61 (4-fold
vs DMSO-treated) and control scrambled shRNA (1.6-fold vs
DMSO-treated) MDA-MB-231Br-based cells, while pretreat-
ment with bafilomycin A1 (BafA1, an inhibitor of autophago-
sosme maturation) promoted autophagy (»2.2-fold) as
revealed by the increase in SQSTM1 expression in KISS1-KD61
cells vs shScrambled control cells (Fig. 6B). Finally, expression
of KISS1 from an adenoviral vector in MDA-MB-231Br cells
Figure 4. MIR-345–5p expression opposes KISS1 in breast cancer cells and primary samples. (A) Relative expression of KISS1 mRNA following transfection of MDA-MB-231
or MDA-MB-231Br cells with either nontargeting miRNA (red bars) or MIR345 mimic (blue bars) precursors as determined by RT-qPCR. (B) Relative expression of a Lucifer-
ase gene reporter with (blue bars) or without (red bars) the hKISS1¡30UTR sequence genetically fused downstream of the reporter-coding sequence in MDA-MB-231Br
cells upon their cotransfection with MIR345 mimic or nontargeting control miRNA. The hKISS1¡30UTR reporter fusion was under control of CMV promoter. Luciferase
activity of samples was normalized to that of negative control and data presented as a relative fold difference § SD. Data represent means of 2 independent experiments
performed in triplicate; P < 0.05 indicates statistical significance determined by a Student t test. (C) Inverse correlation between expression of MIR345–5p and KISS1
mRNA levels in human brain metastatic specimens as determined by RT-qPCR and the Pearson correlation test; Pearson coefficient r D ¡0.67, P D 0.0062; blue bars,
KISS1 mRNA copy number; red bars, human MIR345 copy number both normalized by ACTB and RNU6–2 housekeeping RNA. (D) A Kaplan-Meier survival curve for brain
metastatic patients expressing either high or low levels of MIR345–5p (MIR345) as determined by RT-qPCR in the paraffin-embedded tissue samples. Statistical analysis is
performed by a Log Rank Test, P D 0.017.
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exerted a synergistic effect with 3-Ma treatment by suppressing
autophagy and promoting SQSTM1 expression (4.92-fold).
Conversely, an ectopic expression of KISS1 (Fig. 6C) sup-
pressed autophagy in MDA-MB-231Br cells, upregulated
SQSTM1 (2.5-fold) and exhibited low level of LC3-II (1.75- vs
1.38-fold) in the presence of BafA1 in Ad-infected cells (empty
vector control). Such correlation between KISS1 and SQSTM1
expression on both mRNA (Fig. 6E, P D 0.015) and protein
Figure 5. (For figure legend, see page 1912.)
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(Fig. 6D,F) levels was also observed in human brain metastatic
specimens (immunohistochemical [IHC] staining, Fig. 6D) and
intracranial metastases of MDA-MB-231Br cells (yellow immu-
nofluorescence signal (Fig. 6F), using intracranial route of
tumor cells implantation, suggesting that downregulation of
KISS1 in metastatic BrCa lesions in the brain leads to activation
of autophagy.
Since coculturing of BrCa cells with NHA activates autophagy
via KISS1 downregulation in BrCa cells, we sought to determine
if this activation could improve anticancer properties of auto-
phagy-dependent drugs such as temozolomide (TMZ) used to
improve the efficacy of radiation therapy. Of note, combination
of those approaches requires induction of autophagy.34 In line
with this suggestion, activation of autophagy via KISS1 silencing
increased antiproliferative activity of TMZ (20% to 65% depend-
ing on TMZ concentration) (Fig. 7A,B). Furthermore, prior
treatment of KISS1-KD79 knockdown MDA-MB-231Br cells
with an autophagy inhibitor 3-Ma, reduced TMZ-associated
cytotoxicity 2-fold (P < 0.05) (Fig. 7C,D). These findings under-
line the important role of KISS1 in the mechanism of metastatic
brain tumor sensitivity to cytotoxic agents and suggest high ther-
apeutic potential of autophagy-modulating agents for the treat-
ment of brain metastases.
Downregulation of KISS1 in BrCa cells promotes their
metastatic invasiveness into the brain
To understand the role of KISS1 protein in the fate of BrCa
cells disseminated in the brain we assessed the metastatic
potential of KISS1-deficient cells. Since astrocytes can produce
mediators of metastases, we hypothesized that expression of
CXCL12 could induce metastatic activity in CN34Br and
MDA-MB-231Br cells. Previously KISS1 was reported to sup-
press invasion and migration of both normal6,35 and cancer-
ous36,37 cells. Interestingly, KISS1 expression has previously
been reported to inversely correlate with that of MMP9,38,39
known to promote invasion40,41 and migration42 of BrCa cells.
As shown in Fig. 8A to D, KISS1-deficient cell lines KISS1-
KD61, KISS1-KD79 (MDA231Br-based) and Kiss1-KDA
(4T1Br-based) exhibit a 2- to 3-fold increased migration
toward media enriched with SDF-1a chemokine and 2- to 100-
fold increase in invasiveness (Fig. S8). Whereas inhibition of
autophagy, using RNA interference against human ATG5
(Fig. 8E,F and Fig. S9), decreased invasiveness from 163.8 §
13.8 to 47.4 § 11.4 cells (BrCa 71% reduction, P < 0.0001),
ectopic expression of KISS1 (Fig. 8G,H) in KISS1-deficient cells
repressed autophagy-mediated invasion from 65.4 § 9.21 to
47.6 § 13.1 (»27% reduction, P D 0.017) cells. Additionally,
knockdown of KISS1 mRNA by shRNA silencing induced
expression of MMP9, which inversely correlated with that of
KISS1 in patient tumor specimens43 as revealed by their IHC
staining (the Fisher exact test, P < 0.001) (Fig. 9A). This was
consistent with our earlier findings that MMP9 expression
directly correlates with metastatic progression of BrCa.
Recently, Cheng et al., and earlier Milovanovic et al., have
found a direct correlation between MMP9 and IL8 expression
levels and tumor progression in nasopharyngeal carcinoma44
and BrCa patients,45 respectively. Since expression of MMP9
inversely correlates with expression of KISS1 and directly with
that of IL8,46 we reasoned that expression of KISS1 could nega-
tively affect IL8 expression. Indeed our antibody array data pre-
sented in Fig. S10 demonstrates that downregulation of KISS1
is associated with upregulation of IL8, which, in turn, could
contribute to tumor invasion and metastatic progression. Fur-
thermore, immunofluorescence analysis of brain tumor speci-
mens (Fig. 9B) confirms our in vitro finding that KISS1-specific
staining does not colocalize with that for IL8, whose induction
is linked to cancer metastatic progression possibly via yet
another mechanism.
Discussion
Although normal adult astrocytes are critical for maintaining
brain homeostasis, recent data suggest that they also play an
important role in establishing brain metastases in patients with
advanced form of BrCa.14 The results of our study suggest a
new mechanism for the early stage of BrCa metastases in the
brain that involves a tumor suppressor factor termed KiSS-1
metastasis-suppressor (KISS1). According to the proposed
mechanism, regulation of KISS1 expression, critical for realiza-
tion of metastatic potential of circulating BrCa cells entering
the brain, occurs on post-transcriptional level and involves cel-
lular MIR345. The latter is induced in BrCa cells in response to
chemokine CXCL12 produced in the brain environment by
normal adult astrocytes. Our study provides the first evidence
that a population of circulating BrCa stem cells crossing the
blood brain barrier and entering the brain induces and activates
expression of chemokines in NHA, which in turn mediate
Figure 5. (see previous page) KISS1 regulates autophagy in the brain metastatic cells. (A) Immunofluorescence staining of paraffin-embedded sections of BrCa and brain
metastatic BrCa tissues using anti-KISS1 (red, cytoplasmic and nuclear staining), anti-BCL2 (green, cytoplasmic staining) fluorescently-labeled antibodies and DAPI (blue,
DNA staining) to visualize nuclei. Numerous cells with robust KISS1 expression identified by bright red signal (white arrows) or yellow and orange signal (in cells with visi-
ble colocalization of KISS1 and BCL2 signals), are present in representative tissue specimens. In contrast, brain metastatic BrCa tissue contains almost no KISS1-positive
cells, but large number of cells expressing BCL2 suggesting a correlation between downregulation of KISS1 in metastatic cells and their resistance to apoptosis. Image
magnification is 400X, scale bar: 20 mm. (B) Relative expression of BCL2C- and KISS1C-positive cells detected in 4 BrCa tissue specimens and 4 brain metastatic lesions of
BrCa. The data are presented as amount of BCL2- and KISS1-positive cells detected in the patient samples § SD. All changes are statistically significant (P D 0.0172 calcu-
lated by the Student t test). (C, D) Expression of human KISS1 in Ad-KISS1 vector-transduced MDA-MB-231Br cells results in suppression of autophagy. The cells (2 £ 105)
were infected with Ad or Ad-KISS1 vectors at a multiplicity of infection of 1 and the levels of autophagy-related proteins SQSTM1, LC3-II, ATG5 and ATG7 were analyzed
by western blot (C), followed by densitometry-based semi-quantification, which is presented as a relative protein expression normalized by GAPDH as a loading control
(D); black bars, control adenovirus (Ad)-infected cells; red bars, cells infected with human KISS1-encoding adenovirus (Ad-KISS1). The experiment was performed 3 times
and average data are presented. (E to H) Knockdown of KISS1 by shRNA-mediated silencing induces autophagy in MDA-MB-231Br and 4T1Br cells. The cells were trans-
duced with lentiviral vector or siRNA duplexes to generate stable or transient cell lines with silenced KISS1/Kiss1 expression. Stable cell lines with silenced KISS1 expression
(KISS1-KD61 and KISS1-KD79), based on MDA-MB-231Br (E, (F)top panels), or transient 4T1Br-based cell lines Kiss1-KDA, Kiss1-KDB and Kiss1-KDC with siRNA-silenced Kiss1
expression (G, H), were used to analyze the autophagy response by assessing expression levels of ATG5, ATG7, SQSTM1 as well as LC3 form I to form II conversion rate by
western blot (E, G). Cells expressing shScrambled or noncoding siRNA were used as a nontargeting control. The relative protein expression was quantified by semi-quanti-
tative densitometry (F, H). The experiment was performed 3 times and representative data are shown.
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Figure 6. KISS1 expression correalates with p62/SQSTM1. (A) KISS1 expression reverses autophagy induction in the model of MDA-MB-231Br cells lacking KISS1 expression
(MDA-MB-231Br-KISS1KD). Western blotting assessment of ATG7, LC3, ATG5, SQSTM1 and human GAPDH during KISS1 infection by selfreplicating oncolytic adenovirus. Experi-
ment was conducted twice and data from one experiment are shown. (B and C) KISS1 knockdown promotes autophagy in MDA-MB-231Br cells. (B) Lentivirus-transduced
MDA-MB-231Br cell lines shScrambled or KISS-KD61 were pretreated with DMSO, 1 mM of 3-Ma or 1 nM of BafA1 for 4 h and cell lysates were prepared and analyzed by west-
ern blots 48 h later using 10 mg of total protein loaded on each lane and the membrane was incubated with SQSTM1- or GAPDH-specific antibodies. (C) Ad or Ad-KISS1-trans-
duced MDA-MB-231Br cells were pretreated with DMSO, 1 mM of 3-Ma or 1 nM of BafA1 for 4 h and cell lysates were prepared and analyzed by western blots 48 h later using
10 mg of total protein loaded on each lane and the membrane was incubated with SQSTM1- or GAPDH-specific antibodies. (D to F) Representative IHC or immunofluorescence
images of brain metastatic BrCa (RONC-BM41 and RONC-BM23) human tissue specimens (D, E) or mouse-implanted MDA-MB-231Br human intracranial xenografts (F) stained
for SQSTM1 and KISS1 demonstrate a direct correlation between KISS1 and SQSTM1 gene expression. IHC staining intensity for KISS1 (graded as 0 and 1C) showed direct cor-
relation with that for SQSTM1 (graded as 1C and 2C) in RONC-BM41 and RONC-BM23, respectively (D). Original image magnifications are 200X (scale bar: 50 mm) and 400X
(scale bar: 20 mm); expression of SQSTM1 and KISS1 was visualized using brown dye DAB, conjugated to secondary antibody with background staining with blue dye haema-
toxylin or using an avidin-biotin conjugation system (F). A direct correlation between expression of SQSTM1 and KISS1 was also validated by RT-qPCR analysis of the corre-
sponding gene’s mRNA expression (E) as well as IF staining of murine intracranial MDA-MB-231Br xenografts (MDA231Br ic, (F) counterstained with DAPI using human KISS1-
and SQSTM1-specific antibodies. White arrows indicate BrCa cells with detectable KISS1 (red signal) expression that in most cells colocalizes with SQSTM1 (green signal) pro-
ducing orange foci (white arrows) on the merged (400X) image; scale bar: 20 mm. Spearman correlation test between KISS1 and SQSTM1 mRNA expression was used to ana-
lyze the mRNA expression results (E) (r D 0.99, P D 0.015).
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downregulation of KISS1 expression in those BrCa cancer stem
cells following their localization to the brain. A direct interac-
tion with the astrocytes promotes invasion of the cancer cells
into the brain parenchyma. We showed that a 24-h incubation
of astrocytes (NHA) in the presence of BrCa cells is sufficient
for the induction and release of CXCL12 and CCL2 by those
astrocytes. The results of our experiments are consistent with
high levels of CCL247 and CXCL12 expression found in patients
with advanced stage (metastatic) BrCa.48 We cannot rule out
the possibility of autocrine regulation of CCL2 or CXCL12
(splicing variants such as CXCL12a, CXCL12b or CXCL12g)
expression in astrocytes, especially given the fact that CXCL12a
serves as chemoattractant for the recruitment of immune cells,
such as T cells and monocytes.49,50 Although, expression of
chemokines, such as CCL2 and CXCL12, in normal brain is
low, it can be stimulated in astrocytes by various factors.51 Our
hypothesis is that astrocytes together with monocytes can con-
tribute to brain metastases by secreting CCL2 and CXCL12. A
most recent study by Lee et al. suggests that inhibition of
CXCR4-CXCL12 signaling suppresses migration of circulating
cancer cells through brain endothelium.52
The astrocyte-CN34Br model is unique in that it recapitu-
lates interaction between astrocytes and cancer cells critical
for the onset of brain metastatic disease. Our data also suggest
that the release of CCL2 and CXCL12 by astrocytes facilitates
the survival of the cancer cells in the brain. It is, however, not
clear how secretion of CCL2 and CXCL12 by astrocytes can
also contribute to inflammation as one of the hallmarks of
cancer progression. The latter cannot be ruled out because
expression of inflammatory chemokines is known to promote
metastases. Sensitivity of astrocytes to various stresses is con-
sistent with the induction of chemokines, such as CCL2, by
chemotherapeutics.53,54
Our study suggests that downregulation of tumor suppres-
sor KISS1 could activate expression of proinvasive factors
MMP9 and IL8. We did not aim to investigate the precise
mechanism of MMP9 and/or IL8 upregulation, but our unpub-
lished data suggest that KISS1 silencing can activate expression
of transcription factors TFAP2A/AP-2a, SP1/SP-1 and induce
phosphorylation of inhibitory NFKBIA/IkBa protein, essential
for activation of NFKB1/NF-kB. On this basis, we speculate
that activation of downstream targets, such as IL8, can occur
Figure 7. Downregulation of KISS1 improves sensitivity of BrCa cells to temozolomide (TMZ). To observe KISS1-mediated sensitization of TMZ-resistant MDA-MB-231Br
cells a total of 4 £ 103 cells, stably expressing either a nontargeting (shScrambled control) or a KISS1-targeting (KISS1-KD79) shRNAs, were treated with increasing doses
of TMZ (10 mM, 100 mM and 1 mM) for 72 h. Cell viability was assessed by light microscopy. (A) Phase-contrast images were collected under a 100X magnification; scale
bar: 100 mm; Relative proliferation rates of the control and the KISS1 knockdown cells was determined by MTT assay (B); red bars, shScrambled cells; closed and black
bars, KISS1-KD79 cells. The data are presented as fold (mean § SD) of mock proliferation; statistical significance of the changes (P < 0.05) vs control cells (shScrambled)
was determined using the Student t test. (C) The effect of autophagy inhibitor 3-Ma on sensitivity of BrCa cells with KISS1 knockdown to temozolomide (TMZ) in vitro.
GFP-labeled KISS1-KD79 cells were pretreated with DMSO alone (mock) or 1 mM DMSO solution of 3-Ma for 2 h before 96 hr treatment with 100 mM TMZ. Images were
collected at selected time point using a Nikon Ti-U eclipse microscope under a 200X magnification; scale bar: 50 mm; green fluorescence, GFP-labeled cancer cells. (D)
Quantification of live cells after treatment with TMZ in the presence or absence of autophagy inhibitor 3-Ma (described in C) by trypan blue exclusion test; closed and
black bars, DMSO only/no treatment control; red bars, treatment with 3-Ma in DMSO; blue bar, treatment with 100 mM TMZ alone; green bar, treatment with 100 mM
TMZC3-Ma. Experiment was performed twice in triplicate. Statistical significance of the change relative to the TMZ only-treated group (P D 0.0002) was determined by
the Student t test.
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Figure 8. KISS1-mediated suppression of autophagy promotes cancer cell migration. (A,C, E and G) Transwell motility assays using shScrambled, KISS1-KD61, KISS1-KD79
cells (MDA-MB-231Br-based) (A), noncoding miRNA and Kiss1-KDA (mouse 4T1Br-based) (C), KISS1 stable knockdown MDA-MB-231Br cells transfected with shScrambled
or shATG5 (E) or preinfected with Ad or Ad-KISS1 48 h before loading on Matrigel-coated transwell plates, were performed on 8-mM inserts for 24 h in triplicates. DMEM
supplemented with 10% FBS, serum-free medium, astrocyte-conditioned medium with or without CXCL12, as a chemoattractant, were added to the lower transwell
chamber of each sample. The migrated cells were stained with 0.4% crystal violet and counted. Representative images of MDA-MB-231Br or 4T1Br-based cells were gener-
ated in triplicates from 2 independent experiments under magnification of 400X; scale bar: 20 mm. (B,D, F and H) Quantitative assessment of migrated cells shown in pan-
els (A,C, E and G), respectively. A 2- to 4-fold increase in migration of KISS1-KD61 and KISS1-KD79 cells was observed in both MDA-MB-231Br-based (B) and 4T1Br-based
(D) KISS1 knockout cells. Bars represent the numbers (means § SD) of migrated cells per high power field (HPF).
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via binding of transcription factors to the correspondent pro-
moters and/or binding of the NFKB1/NF-kB-RELA/p50-p65
heterodimer complex to the promoter elements of downstream
genes. The results of our study also suggest that induction of
chemokines by astrocytes leads to upregulation of cellular
microRNAs capable of modulating metastatic potential of can-
cer cells via downregulating KISS1 expression. We discovered
that MIR345 and MIR146B are important effectors of cancer
cell metastatic transformation since they can regulate KISS1.
Besides KISS1, MIR345 and MIR146B regulate as many as 400
different targets involved in angiogenesis, cell adhesion etc.,
some of which also prevent metastatic progression of cancers.
Therefore, future data mining analyses will be performed to
examine the mechanism regulating expression of MIR345 and
its other potential targets as well as their possible relationship.
Interestingly, our findings are consistent with recent data sug-
gesting that CXCL12 activates expression of prometastatic
microRNAs.29 Our data suggest that CXCL12 and CCL2 are
important effectors of metastatic development of BrCa.
Because cancer cell survival is one of the key conditions for
the development of metastases, we addressed the importance of
KISS1 expression for the survival of metastatic cancer cells. We
found that knockdown of KISS1 exerts a stimulating effect on
expression of ATG5, implicated in autophagosome maturation.
Although in our experiments ATG5 gene silencing by an RNA
interference mechanism was validated independently with 3 dif-
ferent ATG5-specific probes at both western blot and real-time
qPCR levels and found to interfere specifically with autophagy-
related cellular signaling, we cannot entirely rule out off-target
effects mediated by siRNA partial complementarity to mRNAs
of other genes.55,56 In our experiments, we observed no changes
in GAPDH or ACTB mRNA expression in the presence of siR-
NAs against human ATG5 gene suggesting specificity of ATG5
mRNA downregulation. Previously, using a hepatocellular carci-
noma model, inhibition of autophagy was found to suppress
tumor growth and improve cytotoxicity mediated by cisplatin.57
Taken together, our data demonstrate that adult astrocytes
mediate suppression of KISS1 expression via the CXCL12-
MIR345 paracrine loop that can promote BrCa cell invasiveness
and survival in the brain. We also show for the first time that
KISS1 knockdown affects downstream targets determining
cancer cell survival and resistance to chemotherapy. Further
studies are needed to identify therapeutic strategies for target-
ing KISS1-negative population of metastatic cancer cells in the
brain, which could potentially improve survival of patients with
advanced BrCa disease.
Materials and methods
Cells
Metastatic BrCa clones “brain seeking clones” of CN34Brm2Ctgl
(CN34Br), GFP and nonlabeled MDA-MB-231Br, and parental
cells CN34TGL (CN34) were obtained from Dr. Patricia Steeg
(Center for Cancer Research, NIH, Bethesda, MD) and Dr. Joan
Massague (Sloan-Kettering Institute, NY) in compliance with the
institutional material transfer agreements. MDA-MB-231 cells
were originally purchased from ATCC (HTB-26). BrCa tumor
circulating cells MDA-MB-231Cherry and MDA-MB-231GFP
(MDA231BrGFP) were obtained from Dr. Dmitry Malin (UW-
Endocrinology) and Jennifer Koblinsky (VCU), respectively. The
MDA-MB-231- and CN34-based cells were cultured in the
media described elsewhere.26,58 Briefly, MDA-MB-231Br cells
were cultured in DMEM/F12 medium supplemented with 10%
fetal bovine serum (FBS; Atlanta Biologicals, S11195H) and 100
U/ml penicillin/streptomycin; CN34 cells were cultured in M199
medium supplemented with 2.5% FBS, 10 mg/ml insulin (Sigma-
Aldrich, I9278), 20 ng/ml EGF (Sigma-Aldrich, 324831), 100 ng/
ml cholera toxin (Sigma-Aldrich, C8052), 0.5 mg/ml hydrocorti-
sone (Fisher Scientific, NC9881403) and 100 U/ml penicillin/
streptomycin.
Primary adult human (1800) and mouse (M1800) astrocytes
and microglia (1907) were obtained from ScienCell and cul-
tured in the media suggested by the vendor. Complete condi-
tioned media was obtained by culturing of primary astrocytes
in media from ScienCell for 6 d without change of media.
Human brain and BrCa specimens
The protocol for the use of primary specimens in the current
study was approved by the Russian Oncology Center, Moscow,
Russia IRB committee. A pilot tissue microarray from 10
Figure 9. KISS1 expression inversely correlates with MMP9 and IL8. (A) Representative images of IHC staining of primary (IDC) and metastatic (RONC-BM21) tumor speci-
mens with MMP9- and KISS1-specific antibodies; 5 mM-matched specimens obtained from the same patients show high expression levels of KISS1 (brown, cytoplasmic
staining) and low levels of MMP9 (brown, membrane and cytoplasmic staining) in the primary BrCa (IDC), but high MMP9 and low KISS1 levels in brain metastases
(RONC-BM21); image magnifications are 200X; scale bar: 50 mm. (B) IF staining of primary metastatic specimen for IL8, CD44 and KISS1 markers. Representative IF staining
for IL8 (pseudocolored with green), KISS1 (pseudocolored with blue), CD44 (pseudocolored with red) is shown with image magnification of 400X; scale bar: 20 mm; White
arrow shows colocalization of IL8 and CD44 in some IL8C, CD44C and KISS1¡ brain metastatic cells (yellow signal, solid arrow). Inset (right image panel) shows a blow-up
image (600X) of the squared area of the tri-color merged 400X image (scale bar: 20 mm).
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patients with brain metastatic disease, matched and unmatched
primary BrCa specimens of BrCa and 5 control patients was
created (Table 1). Primary BrCa tissue samples are: RONC1,
RONC2, RONC4 and RONC10. The brain metastatic BrCa
specimens are: RONC-BM, RONC-BM1, RONC-BM2, RONC-
BM21, RONC-BM23, RONC-BM35, RONC-BM41, RONC-
BM43, RONC-BM61 and RONC-BM321. Additionally, a tissue
microarray containing BrCa from US Biomax (BR1008) was
used for immunofluorescence and immunohistochemistry.
Mouse specimens
Mouse xenografts of human MDA-MB-231Br (MDA231Br)
cells were obtained from an earlier study.23
Drugs and proteins
AMD3100 chemical inhibitor (A5602) and 3-Ma autophagy
inhibitor (M9281) were purchased from Sigma-Aldrich, Bafilo-
mycin A1 (BafA1, 196000) was obtained from Calbiochem-EMD
Millipore and temozolomide (T1849) was obtained from LKT.
Human recombinant CCL2 (MCP-1, 300–04), CCL8 (MCP-
2, 300–15), CXCL1 (GRO-a/MGSA; 300–11), CXCL12 (SDF1a;
AF-300–28A) proteins were purchased from Peprotech.
siRNA and shRNA constructs
shRNA plasmids targeting the human ATG5 gene (Origene,
TG314610; shATG5 versions A, B, C and D) and “scrambled”
negative control (nontargeting shRNA cassette in pGFP-V-RS
vector plasmid TR30013, Origene) were transfected into MDA-
MB-231Br using DharmaFECT1 transfection reagent (GE
Dharmacon, T-2001–01). Selection of stably-transfected clones
was performed using puromycin (Invivogen, ant-pr-1) selec-
tion at 6 mg/mL antibiotic concentration. A mixture of 3 siRNA
duplexes against mouse Atg5 (sc-41446) or Kiss1 genes (ver-
sions Kiss1-KDA [SR402044A], Kiss1-KDB [SR402044B] and
Kiss1-KDC [SR402044C]), and scrambled negative control
siRNA duplex (SR30004), purchased from Santa Cruz Biotech-
nology and Origene, were transiently transfected into 4T1Br
cells.
Viral vectors
Lentiviruses, expressing the 30 UTR of the human KISS1 gene,
shRNAs against human KISS1 (KISS1-KD61 and KISS1-
KD79), or scrambled control shRNA (shScrambled) were
obtained from ABM Inc.).
Recombinant adenovirus construction. The genome of the
conditionally replicative adenovirus with mCherry red fluores-
cent protein on the capsid was constructed by 2-step homolo-
gous recombination (HR) in E. coli (BJ5183 strain) using a
described previously E3/fiber-modified Ad5 backbone vector
Ad5DE1/DE3, F5/359 and a modified E1 shuttle vector, pSlD24-
pIX-mCherry. The E1 shuttle vector contained a fluorescent
reporter mCherry coding sequence,60 inserted downstream of
the Ad5 minor capsid protein IX (pIX) gene via a linker
sequence, encoding a 10-amino acid peptide (SADYKDDDDK)
with an octapeptide flag motif (in bold). The flag was followed
by NheI restriction site used for mCherry coding sequence
(CDS) insertion to generate a pIX-Flag-mCherry fusion with
expression controlled by the native pIX promoter. The shuttle
also harbored a 24-base pair deletion in the Ad5 E1A gene cod-
ing sequence (“D240), as described previously, to render Ad5
Table 1. Characteristics of specimens used in this study.
Specimen
/tissue type
Specimen
name
Patient live
status*
Age at IDC
diagnosis IDC grade
Brain Met year
of diagnosis TNM ER PR HER-2
Brain Metast. Sample RONC-BM living 61 IIB 2000 T1N0M0 Neg Neg Neg
RONC-BM1 living 67 III 2004 T2N1M0 Neg Neg Pos
RONC-BM2 deceased 45 IIa 2005 T2N0M0 Neg Neg Neg
RONC-BM21 living 75 II 2002 T2N0M0 Neg Neg Neg
RONC-BM23 living 31 II 2005 T2N1M0 Neg Neg Pos
RONC-BM31 living 59 III 2002 T2N1M0 Neg Neg Pos
RONC-BM34 deceased 65 III 2005 T1N1M0 Neg Neg Pos
RONC-BM37 deceased 57 IIIa 1996 T2N0M0 Neg Neg Pos
RONC-BM39 deceased 70 IIIa 2005 T3N2M0 Neg Neg Neg
RONC-BM41 living 35 III 2008 T2N1M0 Neg Neg Pos
RONC-BM43 living 71 III 2006 T2N0M0 Pos Pos Pos
RONC-BM47 deceased 68 III 2003 T2N0M0 Neg Neg Neg
RONC-BM61 living 47 IIIa 1994 T2N2M0 Neg Neg Neg
RONC-BM74 living 59 III 2004 T2N0M0 Pos Pos Pos
RONC-BM321 deceased 50 IIB 2007 T2N1M0 Pos Neg Neg
Primary BrCa Sample RONC1 living 79 III T2N0Mx Pos Pos Neg
RONC2 living 66 III T2N2Mx Pos Pos Neg
RONC4 living 40 II T1N0Mx Pos Pos Neg
RONC10 living 75 III T2N2aMx Pos Pos Pos
Normal breast tissue Normal1 living 45 T0N0M0
Normal2 living 40 T0N0M0
Normal3 living 37 T0N0M0
Normal4 living 39 T0N0M0
Normal5 living 33 T0N0M0
Abbreviations: Status as of 11/11/2015; BrCa – breast cancer; IDC grade – the grade of invasive ductal carcinoma (IDC) in patients when diagnosed with brain metastases;
TNM-breast cancer staging based on tumor size, cancer spreading to lymph nodes and metastasis occurrence; ER, PR and HER2- status of estrogen, progesterone and
HER2 receptors in tissue specimens detected by immunohistochemistry, respectively. Neg- negative status; Pos- positive status;
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replication selective for cancers with disrupted retinoblastoma
(Rb) tumor suppressor pathway.61
The intermediate backbone vector Ad5DE1/DE3, CMV-
KISS1, F5/3 was generated by HR in bacteria between the fiber
gene-modified vector Ad5DE1/DE3, F5/362 and an E3 shuttle
vector, harboring deletion of the E3 region sequence starting
from the last 44 bases of the E3A 12.5K gene CDS up to the last
18 nucleotides of the E3B 14.7K CDS. The KISS1 cassette was
PCR amplified using sense and antisense primers and cloned
into the unique SalI site of the above E3 shuttle downstream of
the SwaI site-flanked kanamycin (Kan) gene. Following homol-
ogous recombination (HR) of the fiber-deleted backbone plas-
mid with the modified E3 shuttle recombinant clones were
screened using 2 sequential PCR-assays detecting Ad5 pIX (or
Ad5 hexon) gene-specific sequences followed by detection of
the 30 knob sequences of the F5/3 fiber chimera. Since the E3
shuttle vector carried the wild-type fiber gene sequence as part
of one of its “recombination arms” (RA), the latter assay was
performed to verify that HR occurred upstream of the Ad3
knob domain sequence of the Ad5DE1/DE, KISS1, F5/3 back-
bone vector and the Ad3 knob sequence of the F5/3 chimera
fiber gene was not replaced by the Ad5 knob sequence of the
E3 shuttle. Incorporation of the Kan gene in the intermediate
backbone plasmid allowed selecting recombinants on 2 antibi-
otics: Amp and Kan. Following HR of the Ad5DE1/DE3, CMV-
Kiss1, F5/3 with the PmeI-linearized E1 shuttle vector
pSlD24E1, pIX-mCherry and colony selection on Kan, the E1
recombinants were screened using a PCR assay. The accuracy
of HR was additionally verified by restriction digest with Hin-
dIII and NheI. A mixture of 2 nonrecombined plasmids was
used as a control to account for a strand switch as a possible
mechanism for false-positive signal. Miniprep plasmid DNA
isolated from positive BJ clones was retransformed in the stable
strains STBL4 or DH5-a (Invitrogen), and following colony
rescreening and plasmid upscaling, linearized with PacI and
transfected into the HEK-293 helper cells with Lipofectamine
2000 (Thermo Fisher-Invitrogen, 11668027).
Generation and molecular validation of conditionally
replicative adenoviruses (CRAds)
All viruses were generated and plaque-purified in E1-comple-
menting retinoblastoma 911 cells according to standard proce-
dures. The CRAds were propagated in A549 adenocarcinoma
cells. All viruses were purified by double cesium chloride ultra-
centrifugation (AdEasy system; QBiogene-MP, 11AES2016)
and dialyzed against phosphate-buffered saline (Fisher Scien-
tific, 20–012–027) with 10% glycerol. Viral particle titer for the
purified preparations of each virus was determined by absor-
bance at 260 nm as described previously.62 The absence of con-
tamination with the wild-type E1A sequence-containing
genomes (known as RCA) in virus preparations as well as geno-
mic identity of each virus was verified by conventional PCR
assays. Incorporation of pIX-mCherry fusion protein in the
viral capsids and their molecular integrity was confirmed by
western blot as using mouse monoclonal ANTI-FLAG M2
(Sigma-Aldrich, F3165). Antibody binding was detected using
the ECLTM chemiluminescence detection system (GE Health-
care, 45–002–401). Infectious titers were determined in
HEK-293 helper cells by the 50% tissue culture infectious dose
(TCID50) method. The limiting dilution end point and infec-
tious titer (TCID50/ml) were determined by the K€arber equa-
tion: TCID50/ml D 10[1CD(S-0.5)]/V, where D is the
logarithm of the dilution factor (e.g., D D 1 for the 10-fold
serial dilution), S is the logarithm of the initial dilution plus the
sum of ratios of infection-positive wells per total wells at each
subsequent dilution, and V is the volume of the diluted vector,
used for inoculation, in milliliters (ml).
Antibodies for immunoblotting, immunofluorescence and
histology
The following primary antibodies were used for western blot-
ting: rabbit anti-ATG5 (Cell Signaling Technology, 2630), anti-
ATG7 (Cell Signaling Technology, 2613), anti-SQSTM1/p62
(Abcam, EPR4844), anti-LC3A/B (Novus Bio, NB100–233),
anti-MMP14 (Abcam, AB38971), anti-MMP9 (Cell Signaling
Technology, 2270) mouse anti-hexon (EMD Millipore,
MAB8044), anti-GAPDH (EMD Millipore, MAB374); rabbit;
for immunofluorescence: rabbit anti-KISS1 (Sigma-Aldrich,
K0394), anti-BCL2 (Epitomics-Abcam, AP1303a), anti-CD24
(LSBio, c41096), anti-CD44 (Novus Bio, NBP1–41266) anti-
CCL2 (GeneTex, GTX81767) anti-CXCL12 (LSbio, LS-
c167170) and mouse FITC-labeled anti-FLOT2/ESA1 (Gene-
Tex, GTX33201), anti-GFAP (Molecular Probes, A21282); and
histology: rabbit anti-MMP9 (Novus Bio, NB110–57222) and
mouse anti-KISS1 (clone 6a4.27) provided by D. R. Welch
(KUMC).
Infection of BrCa cells
A) CN34Br or MDA-MB-231Br cells were labeled with pre-
made lentiviruses expressing codon optimized RFP
reporter under control of the CMV promoter (GenTar-
get Inc., LVP023).
B) Rescue of stably-transfected BrCa cells with shRNA-
silenced KISS1 gene expression. The DNA sequence
encoding shRNA for the human KISS1 gene or scram-
bled shRNA was cloned into pLKO-based lentivirus vec-
tor (Sigma-Aldrich, SHCLNV-HM_002256) and
MISSION KISS1 shRNA lentiviral transduction particles
were used. The MDA-MB-231Br cells were infected
with either TRCN0000059067 (clone61) or
TRCN0000059063 (clone79) lentiviral particles, which
deliver shRNA against CDS of human KISS1 gene
(NM_002256) or Scrambled shRNA according to the
protocol provided by the vendor and after 3 d subjected
to puromycin selection in complete medium supple-
mented with 5 mg/ml of antibiotic (Invivogen, ant-pr-1)
for 14 d. The level of KISS1 knockdown was determined
by quantitative RT-PCR.
C) Generation of puromycin-resistant CN34Br cells express-
ing a GFP-KISS1¡30UTR reporter fusion. Stable expres-
sion of GFP-KISS1¡30UTR reporter construct was
achieved by using lentivirus-based vectors (Applied Bio-
logicals Materials, MV-h61814) carrying GFP fused to
30UTR region of the KISS1 gene. Stable expression of
Target cells plated in 96-well plate were infected with
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the above lentiviruses and 24 h later virus-containing
culture media was replaced with complete media supple-
mented with 1.2 mg/ml of puromycin. Puromycin-resis-
tant clones were selected by culturing transfected cells
for 2 wk under selective conditions.
Cell proliferation
MTT cell proliferation assay was performed according to the
manufacturer’s instruction for the Cell proliferation kit I
(Roche, 11465007001). Results were expressed as a ratio
between treated and untreated (mock) cells multiplied by
100%. Four wells were sampled as replicates per each experi-
mental group in a given experiment. Data values are presented
as means § standard deviation.
Cell viability-calcein AM test
Cell membrane integrity was evaluated after transfection of
cancer cells with siRNA, shRNA plasmids or infection with 1
multiplicity of infection of Ad or Ad-KISS1 vectors by incuba-
tion of the cells with 2 mM calcein-AM. The assay was per-
formed in 96-well plates as recommended by the vendor with
300 ml well volume (0.32 cm2 growth area) and 100-ml sample
volume per each well.
Boyden and Invasion assays
The migration property of MDA-MB-231Br based cells lacking
KISS1 (KISS1-KD61, KISS1-KD79 or shScrambled) pretreated
with mock, adenovirus (Ad) or Ad-KISS1 vectors, 4T1Br-based
transient transfected cells with Kiss1-KDA or shScrambled con-
trol was assessed using the Boyden assay. Briefly, 5 £ 104 can-
cer cells were seeded in the top chamber of the BD cell
migration system either covered (invasion test) or not covered
with Matrigel (migration test;Trevigen, 3433–001–01). As a
chemoattractant DMEM media supplemented with 10% FBS,
serum-free DMEM (SF medium), normal astrocyte media (Sci-
enCell, 1801) supplemented with astrocyte growth supplement
(ScienCell, 1852) or astrocyte conditioned medium (Scien-
Cell,1811-sf) supplemented with CXCL12/SDF1 (10 mg/ml;
Peprotech, 300–28A) were used. Following a 24-h incubation,
the number of migrating cells per field was counted using an
Zeiss Axiovert 135 inverted microscope (Thornwood, NY,
USA) at 10X magnification. A minimum of 8 images were col-
lected and processed via MetaMorph software (Olympus,
Japan).
Luciferase assay
MDA-MB-231Br cells were plated at a density of 5 £ 104 cells
per well in a 96-well plate 24 h before transfection. The next
day, GoClone plasmids expressing fusion constructs of Lucifer-
ase reporter gene and the 30UTR sequences containing either
the MIR345 binding site, mutated MIR345 binding site or con-
trol vector were mixed (at a concentration of 30 ng/ml) with
Gibco OPTI-MEM medium (Fisher Scientific, 31–985–062),
MIR345 mimic (SwicthGear Genomics, MIM0334), nontarget-
ing (SwitchGear Genomics, MIM9001), and Fugene HD
reagent (Promega, E2311) as per the protocol recommended by
SwitchGear Genomics (Carlsbad, CA). After 30 min of incuba-
tion, 5 ml of transfection mixture was added to the each well.
Cells were incubated for the next 48 h before measuring lucifer-
ase activity using a LightSwitch Assay kit (SwitchGear Geno-
mics, LS010).
GFP analysis of KISS1 inhibition by MIR345-mimic
For analysis of GFP activity, CN34Br cells stable expressed
GFP-KISS1¡30UTR fusion were plated in 24-well culture plate
24 h before treatment with NHA conditioned media alone or
in combination with AMD3100, serum-free media supple-
mented with CCL2 or CXCL12, transfection with noncoding
MIR-mimic (20 nM; GE Healthcare, CN-00100) or MIR345-
mimic (MIR345–5p, 20 nM; GE Healthcare, c-300711)
MIR345-mimic or nontargetingMIRmimic were delivered into
target cells using DharmaFECT1 (GE Healthcare, T-2001).
Activity of GFP expression was determined 48 h after transfec-
tion. From 5 to 8 GFP images were captured by phase-contrast
fluorescent microscopy and signal intensity from region of
interest (ROI) was assessed by ROI manager (ImageJ software).
Angiogenesis array
Semi-quantitative analysis of human cytokines was performed
using a sandwich-based membrane-antibody array C1000
(AAH-ANG-1000) according to the vendor’s recommenda-
tions (RayBiotech). Images were acquired with a Gel Doc XR
System (Bio-Rad, Hercules, CA, USA) and analyzed relative to
a positive control.
ELISA
Cells were seeded at the density of 50,000 cells per well 24 h
before infection with a replication competent adenoviral vector
expressing KISS1 (Ad-KISS1) or an “unarmed” control vector
(Ad). After 24 h of infection an unbound virus containing
media was replaced with either a complete media or a serum-
free medium (ELISA test) for the next 48 h of incubation. At
72 h post infection, supernatant from cells was harvested as per
the manufacturer’s instructions (KISS1 Enzyme Immunoassay
Kit; Phoenix Pharmaceuticals Inc., EK-048–56). Detection of
human KISS1 was performed by using biotinylated rabbit anti-
KISS1 antibodies (Phoenix Pharmaceuticals Inc., EK-048–56)
and streptavidin-horse radish peroxidase (HRP) conjugate
(Phoenix Pharmaceuticals Inc., EK-SA-HRP). Signal was
detected upon addition of the substrate solution (TMB; Phoe-
nix Pharmaceuticals Inc., EK-SS) and measuring absorbance at
450 nm wavelength as per the vendor’s protocol. Four wells
were sampled per each experimental group and absorbance
presented as mean § standard deviation (SD).
Flow cytometry analyses
mCherry-positive CTCs were detected in the blood by flow
cytometry using BD FACSAria Cell sorter (BD Biosciences, San
Jose, CA). Blasticidin-resistant blood-derived MDA-MB-231
AUTOPHAGY 1919
cells (CTC) were expanded and then stained with CD44, CD24
and EPCAM antibodies.21
Immunoblot analysis
Approximately 2 £ 105 cells were lysed in 1X NP40 (Calbio-
chem, 492018)-based extraction buffer (20 mM HEPES, pH
7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP40,
1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml
aprotinin, 1 mg/ml leupeptin, 250 mg/ml benzamide, 50 mM
NaF, and 1 mM NaO3V4) and HaltTM Protease Inhibitor Cock-
tail (Pierce-Thermo Scientific, 78429). Ten mg of total protein
per sample was loaded onto a gel. After incubation with pri-
mary antibodies overnight, membranes were probed with either
the secondary HRP goat anti-mouse antibody (Bio-Rad,
1721011), or HRP goat anti-rabbit antibodies (Bio-Rad,
1721019), and visualized with a Bio-Rad Imaging Station (Bio-
Rad). Protein expression was quantified by band densitometry
analysis using a Chemidoc Touch Imaging System (BioRad,
Hercules, CA, USA) and data from 2 independent experiments
were plotted vs housekeeping protein controls. Data were pre-
sented as fold change in protein expression level relative to that
of the corresponding protein in scrambled shRNA construct-
transfected cells.
RT-PCR and quantitative RT-PCR
A) Detection of cellular mRNAs. Extraction of total RNA
from treated or untreated BrCa cells and human astro-
cytes was performed by using an RNeasy Mini Kit (Qia-
gen, 74104). Reverse transcription was performed using
an iScriptTM cDNA Synthesis kit (Bio-Rad, 1708890).
Quantitative RT-PCR analysis was performed in tripli-
cate by using the Power SYBRR PCR Master Mix
(Applied Biosystems-Thermo-Fisher Scientific,
4368577) or iQ SYBR Green Supermix (Bio-Rad, 170–
8880) according to the manufacturer’s instructions, in a
10-ml reaction volume. Samples were run on a Bio-Rad
Opticon II PCR station (Bio-Rad, Hercules, CA, USA)
or ABI 7900HT Cycler (Applied Biosystems-Life Tech-
nologies,Waltham, MA). Expression levels were normal-
ized to that of the human Actin (ACTB) gene.
Amplification specificity was verified by melting curve
analysis and agarose gel electrophoresis.
B) Detection of cellular miRNAs. Total RNA containing
microRNA and mRNAs were extracted from formalin-
fixed paraffin embedded tissue using an FFPE RNA
extraction Kit (Qiagen, 73504) and from adherent cells
using TRIzol reagent (Thermo Fisher Scientific,
15596026) according to the manufacturer’s instructions.
The quality of isolated RNA was determined with an
Agilent and ND1000 Nanodrop Spectrophotometer
(Nanodrop Technology-Thermo Scientific, Wilmington,
DE, USA) before cDNA conversion using qScript miR
cDNA Synthesis (Quanta Biosciences, 95107–100). The
level of selective miRNAs expression was established by
using PerfeCTa SYBR Green PCR SuperMix microRNA
assay (Quanta Biosciences, 95053–500), miRNA specific
assay (HSMIR-0345–5P) relative to cellular RNU6–2
(HS-RNU6). The comparative DDCt method was used
to calculate the relative changes in gene expression by
using an OPICON 2 Real time PCR machine (Bio-Rad).
Soft agar colony formation assay: In vitro tumorigenicity
analysis
A methylcellulose colony formation assay was performed as
described. Briefly, soft agar assays were performed by plating
suspension of 1 £ 104 cells in 1% low melting agarose. Cell col-
onies stained with 0.005% crystal violet colonies were counted
14 d later by drawing the grid on the plate. Experiments were
repeated twice in triplicates.
Immunohistochemistry
Human brain or BrCa tissues were fixed overnight in 10% for-
malin solution (Thermo-Fisher Scientific, SF98–4). Five-
micron-thick sections were deparaffinized, rehydrated and
quenched in 1% hydrogen peroxide in methanol. Antigen
retrieval was performed in 10 mM sodium citrate, pH 6.0, 0.1%
Tween-20 (Fisher BioReagents, BP337–500). Blocking was
done in 10% normal serum (Vector Laboratories, S-5000), 1%
BSA (Sigma-Aldrich, A2153), and 0.1% Tween-20, followed by
incubation with the primary antibodies diluted in 1% BSA
overnight at 4C. After incubating with secondary HRP-conju-
gated antibody, sections were developed with DAB Peroxidase
(HRP) Substrate Kit (Vector Laboratories, SK-4100). Slides
were counterstained with Gill’s hematoxylin-eosin (Sigma-
Aldrich, 1051740500), and mounted with Histomount (Fisher
Scientific-National Diagnostics, 50–899–90137) before exami-
nation on a Zeiss AxioImager A2 microscope (Zeiss, Thorn-
wood, NY).
Immunofluorescence
To determine the colocalization of CD24 and CD44, CCL2 and
GFAP, CXCL12 and GFAP, EPCAM with CD44 and CD24,
KISS1 with CD44 and GFAP markers, we performed immuno-
fluorescent multicolor staining. Antigen retrieval was per-
formed in citrate buffer, pH 6.0. The blocking step was
performed by incubating the slides with Background Buster
(Accurate Chemical & Scientific Corporation, NB306/50) and
endogenous biotin activity was quenched followed by incuba-
tion with mouse antibody, rabbit antibody, or Alexa Fluor 488-
labeled rabbit antibody (Novus Bio, NB110–89474AF488). The
secondary biotinylated antibody (Vector Laboratories, BA-
9200) treatment was followed by Streptavidin-Alexa Fluor 594
conjugate (Life Technologies – Molecular Probes, S32356). For
negative controls the treatment was exactly the same except
that the primary antibody was omitted. Slides were mounted in
VECTASHIELD Antifade mounting medium containing DAPI
(Vector Laboratories, H1200). Protein expression in tissue sec-
tions were visualized using a Leica SP5 AOBS Laser Scanning
confocal microscope (Solms, Germany) with x90 (1,3 NA) or
x60 (1.45 NA) oil objectives, or confocal images of immuno-
fluorescently stained cells grown on coverslips were acquired
with an Nikon Eclipse Ti-U microscope (Tokyo, Japan) and
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images were captured by a Nikon digital sight DS-Qi1Mc cam-
era, imported into and analyzed by IP Labs.
Orthotopic MDA-MB-231 BrCa model
The MDA-MB-231-mCherry model was established as
described previously.23 Fourteen, 28 and 42 d later, blood sam-
ples (1 ml) were collected from the heart, purified using GE
HelathcareTM PercollR centrifugation media (Fisher Scientific,
45–001–748) gradient centrifugation,24 and cultured in
medium containing 1 mg/ml blasticidin (Sigma-Aldrich,
203351). One wk later, Cherry-positive cells were subjected to
flow cytometry using antibodies against CD24, CD44 and
EPCAM markers. At 2, 4 and 6 wk post tumor implantation
the number of mCherry-positive cancer cells was determined
by Flow cytometry.
Statistics
All statistical analyses were performed using GraphPad Prism
software. Statistical analysis of the data was performed using
the Student unpaired t test, as indicated in the figure legends. A
Log Rank test was using to compare the Kaplan-Meier survival
curves. All experiments were performed twice and indepen-
dently; P values <0.05 in all cases indicate statistical
significance.
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